Janus 激酶抑制剂：治疗中轴型脊柱关节炎的新工具。
Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis.
机构信息
Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.
Eye Clinic, Department of Sense Organs, Sapienza University of Rome, 00185 Rome, Italy.
出版信息
Int J Mol Sci. 2023 Jan 5;24(2):1027. doi: 10.3390/ijms24021027.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease involving the spine, peripheral joints, and entheses. This condition causes stiffness, pain, and significant limitation of movement. In recent years, several effective therapies have become available based on the use of biologics that selectively block cytokines involved in the pathogenesis of the disease, such as tumor necrosis factor-α (TNFα), interleukin (IL)-17, and IL-23. However, a significant number of patients show an inadequate response to treatment. Over 10 years ago, small synthetic molecules capable of blocking the activity of Janus kinases (JAK) were introduced in the therapy of rheumatoid arthritis. Subsequently, their indication extended to the treatment of other inflammatory rheumatic diseases. The purpose of this review is to discuss the efficacy and safety of these molecules in axSpA therapy.
中轴型脊柱关节炎（axSpA）是一种累及脊柱、外周关节和附着点的慢性炎症性疾病。这种疾病会导致僵硬、疼痛和运动功能显著受限。近年来，已有多种有效的治疗方法问世，这些方法基于使用生物制剂，这些生物制剂选择性地阻断疾病发病机制中涉及的细胞因子，如肿瘤坏死因子-α（TNFα）、白细胞介素（IL）-17 和 IL-23。然而，仍有相当数量的患者对治疗反应不足。十多年前，能够阻断 Janus 激酶（JAK）活性的小分子合成药物被引入类风湿关节炎的治疗中。随后，其适应证扩展到其他炎症性风湿性疾病的治疗。本文旨在讨论这些分子在 axSpA 治疗中的疗效和安全性。
Zotero 插件